Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

B-cell-activating factor affects the occurrence of thyroid autoimmunity in chronic hepatitis C patients treated with interferon alpha.

Kajiyama Y, Kikuchi K, Takai A, Hosoya N, Hoshino H, Hino K, Miyakawa H.

Clin Dev Immunol. 2012;2012:247973. doi: 10.1155/2012/247973. Epub 2012 Feb 27.

2.
3.

Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C.

Friedrich-Rust M, Theobald J, Zeuzem S, Bojunga J.

J Viral Hepat. 2009 Mar;16(3):168-77. doi: 10.1111/j.1365-2893.2008.01059.x. Epub 2008 Oct 17.

PMID:
19175874
4.

Impact of sex on virologic response rates in genotype 1 chronic hepatitis C patients with peginterferon alpha-2a and ribavirin treatment.

Yu JW, Sun LJ, Zhao YH, Kang P, Yan BZ.

Int J Infect Dis. 2011 Nov;15(11):e740-6. doi: 10.1016/j.ijid.2011.05.018. Epub 2011 Jul 30.

5.

[Clinical observation of Hashimoto thyroiditis in patients with chronic hepatitis C undergoing pegylated-interferon alpha-2a and ribavirin combination therapy].

Teng ZL, Gong WJ, Zhang SQ, Sun YX, Ma XH.

Zhonghua Gan Zang Bing Za Zhi. 2013 Feb;21(2):101-4. doi: 10.3760/cma.j.issn.1007-3418.2013.02.007. Chinese.

PMID:
23663880
6.
7.

[Extrahepatic manifestations of chronic hepatitis C and their influence on response to treatment with pegylated interferon alfa-2a and ribavirin].

Fabri M, Ruzić M, Lendak D, Preveden T, Fabri I, Petrić V.

Srp Arh Celok Lek. 2013 May-Jun;141(5-6):320-4. Serbian.

8.

The effect of pegylated interferon-alpha2b and ribavirin combination therapy for chronic hepatitis C infection in elderly patients.

Nishikawa H, Iguchi E, Koshikawa Y, Ako S, Inuzuka T, Takeda H, Nakajima J, Matsuda F, Sakamoto A, Henmi S, Hatamaru K, Ishikawa T, Saito S, Kita R, Kimura T, Osaki Y.

BMC Res Notes. 2012 Mar 10;5:135. doi: 10.1186/1756-0500-5-135.

9.

Efficacy of pegylated interferon and ribavirin combination therapy for patients with hepatitis C virus infection after curative resection or ablation for hepatocellular carcinoma--A retrospective multicenter study.

Harada N, Hiramatsu N, Oze T, Tatsumi T, Hayashi N, Takehara T.

J Med Virol. 2015 Jul;87(7):1199-206. doi: 10.1002/jmv.24173. Epub 2015 Mar 13.

PMID:
25772024
10.

Pegylated interferon alfa and ribavirin for children with chronic hepatitis C.

Rosen I, Kori M, Eshach Adiv O, Yerushalmi B, Zion N, Shaoul R.

World J Gastroenterol. 2013 Feb 21;19(7):1098-103. doi: 10.3748/wjg.v19.i7.1098.

11.

Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.

Hung CH, Lu SN, Wang JH, Hu TH, Chen CH, Huang CM, Lee CM.

Antivir Ther. 2011;16(7):959-68. doi: 10.3851/IMP1842.

PMID:
22024511
12.

[Individualization of antiviral treatment of chronic hepatitis].

Konstantinov DIu, Konstantinova EA, Strebkova EA, Popova LL, Suzdal'tsev AA.

Eksp Klin Gastroenterol. 2013;(6):29-34. Russian. No abstract available.

PMID:
24772857
13.

[Effect of interferon and ribavirin combination therapy in sixty-two patients with chronic hepatitis C originating from a single blood donor].

Liu SD, Cheng ML, Ren H, Yang QK, Shu DY.

Zhonghua Gan Zang Bing Za Zhi. 2012 Aug;20(8):589-92. doi: 10.3760/cma.j.issn.1007-3418.2012.08.010. Chinese.

PMID:
23207152
14.

[Thyroid dysfunctions in children with chronic hepatitis C during interferon alpha-2b therapy].

Kupś-Rzepecka J, Woźniakowska-Gesicka T, Gołabek V.

Przegl Lek. 2011;68(6):311-5. Polish.

PMID:
22039668
15.

Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.

Galán RJ, Cidoncha EC, Martin MF, Rodriguez CC, Almeida CV, Verdugo RM.

J Manag Care Pharm. 2013 Jul-Aug;19(6):448-53.

16.

[Efficacy of combination therapy with pegylated-interferon alfa-2a plus ribavirin in autoantibody-positive chronic hepatitis C patients].

Li YX, Yang YJ, Yang M, Chen LY, Lu JJ, Ma YJ, Liu K, Lei XZ, Tang H.

Zhonghua Gan Zang Bing Za Zhi. 2013 May;21(5):345-7. doi: 10.3760/cma.j.issn.1007-3418.2013.05.008. Chinese.

PMID:
24025134
17.

Thyroid autoantibodies and thyroid dysfunction during treatment with interferon-alpha for chronic hepatitis C.

Kiehne K, Kloehn S, Hinrichsen H, Gallwitz B, Mönig H.

Endocrine. 1997 Jun;6(3):231-4.

PMID:
9368677
18.

Comparative therapeutic response to pegylated interferon plus ribavirin versus interferon alpha-2b in chronic hepatitis C patients.

Ali S, Nazir G, Khan SA, Iram S, Fatima F.

J Ayub Med Coll Abbottabad. 2010 Oct-Dec;22(4):127-30.

PMID:
22455279
19.

Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy.

Lange CM, Kutalik Z, Morikawa K, Bibert S, Cerny A, Dollenmaier G, Dufour JF, Gerlach TJ, Heim MH, Malinverni R, Müllhaupt B, Negro F, Moradpour D, Bochud PY; Swiss Hepatitis C Cohort Study Group.

Hepatology. 2012 Apr;55(4):1038-47. doi: 10.1002/hep.24787. Epub 2012 Feb 9.

PMID:
22095909
20.

Immunogenicity of recombinant hepatitis B vaccine in treatment-naive and treatment-experienced chronic hepatitis C patients: the effect of pegylated interferon plus ribavirin treatment.

Elefsiniotis IS, Vezali E, Kamposioras K, Pantazis KD, Tontorova R, Ketikoglou I, Moulakakis A, Saroglou G.

World J Gastroenterol. 2006 Jul 21;12(27):4420-4.

Supplemental Content

Support Center